for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Brickell Biotech Inc

BBI.N

Latest Trade

0.66USD

Change

0.01(+0.95%)

Volume

9,263

Today's Range

0.66

 - 

0.68

52 Week Range

0.47

 - 

3.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.65
Open
0.67
Volume
9,263
3M AVG Volume
46.02
Today's High
0.68
Today's Low
0.66
52 Week High
3.95
52 Week Low
0.47
Shares Out (MIL)
53.52
Market Cap (MIL)
35.05
Forward P/E
-0.92
Dividend (Yield %)
--

Latest Developments

More

Brickell Biotech Inc - R. Michael Carruthers, CFO And Principal Accounting Officer, Will Be Resigning

Brickell Biotech Inc - Kaken Plans To Launch ECCLOCK For Treatment Of Primary Axillary Hyperhidrosis In Japan On November 26, 2020

Brickell Biotech Reports Q3 Revenue Of $100,000

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Brickell Biotech Inc

Brickell Biotech, Inc., formerly Vical Incorporated, is a clinical-stage pharmaceutical company that focuses on the development of therapeutics for the treatment of skin diseases. The Company’s pipeline consists of molecular entities targeting the treatment of the indications, such as hyperhidrosis, cutaneous T-cell lymphoma, allergic contact dermatitis, psoriasis and androgenic alopecia. The Company’s product candidates include BBI-3000, BBI-6000 and Sofpironium Bromide. Sofpironium Bromide is a topical soft anticholinergic for axillary hyperhidrosis. BBI-3000 is an oral rexinoid for cutaneous T-cell lymphoma. BBI-6000 is a retinoic acid-related orphan nuclear receptor gamma antagonist, which is develops for psoriasis.

Industry

Biotechnology & Drugs

Contact Info

5777 Central Ave Ste 102

BOULDER, CO

80301-2870

United States

+1.720.5054755

https://brickellbio.com/

Executive Leadership

Reginald L. Hardy

Chairman of the Board, Co-Founder

Robert B. Brown

Chief Executive Officer, Director

Andrew D. Sklawer

Co-Founder, Chief Operating Officer, Secretary

R. Michael Carruthers

Chief Financial Officer

Jose Breton

Chief Accounting Officer, Controller

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2020(E)

0.0K
EPS (USD)

2017

-7.070

2018

-5.180

2019

-4.500

2020(E)

-0.710
Price To Earnings (TTM)
--
Price To Sales (TTM)
14.23
Price To Book (MRQ)
1.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
2.34
LT Debt To Equity (MRQ)
0.91
Return on Investment (TTM)
-113.66
Return on Equity (TTM)
-84.50

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up